Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7801946 | 0.95 | NR1D1 (0.33) | NR1D1CYP1A2NR1H3 | |
| SCHEMBL422349 | 0.93 | CHRM2 (0.36) | NR1D1CYP1A2NR1H3CA14HDAC1 | |
| SCHEMBL2185396 | 0.89 | NR1D1 (0.35) | NR1D1NR1H3CA14CA12CA1 | |
| SCHEMBL7564036 | 0.88 | NR1D1 (0.36) | NR1D1NR1H3CA14CA12CA1 | |
| Hydrochloric Acid SCHEMBL6840742 | 0.87 | NR1D1 (0.34) | NR1D1NR1H3CA14CA12CA1 | |
| SCHEMBL8412077 | 0.85 | NR1D1 (0.34) | NR1D1NR1H3CA14CA12CA1 | |
| SCHEMBL18362362 | 0.85 | NR1D1 (0.33) | NR1D1NR1H3CA14CA12CA1 | |
| SCHEMBL2185399 | 0.82 | TDP1 (0.43) | NR1D1NR1H3CA1 | |
| SCHEMBL21548073 | 0.82 | NR1D1 (0.33) | NR1D1NR1H3 | |
| SCHEMBL19458 | 0.82 | TDP1 (0.42) | NR1D1NR1H3CA14CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| EP-0941120-A4 | BRANCHED PEPTIDE LINKERS | BRISTOL MYERS SQUIBB CO (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-0941120-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998019705-A1 | BRANCHED PEPTIDE LINKERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | NR1D1 133/4885CYP1A2 1060/4885NR1H3 92/4885 |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | GPR119, GPR65, GPR55 | NR1D1 385/4885CYP1A2 971/4885NR1H3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.